Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPL7013 Gel for Prevention of Recurrent Bacterial Vaginosis
NCT02237950Phase 3Completed
- Sponsor
- Starpharma
- Start
- Oct 2014
- Primary completion
- Dec 2016
- Modality
- Peptides, Polymer-based Nanoparticles
- Countries
- 3
01
Overview
Phase 3, randomised, double-blind trial in bacterial vaginosis (BV) comparing 1% SPL7013 Gel with Placebo Gel (2 arms). Primary endpoint: Recurrence of Bacterial Vaginosis defined by at least 3 Amsel criteria at 16 weeks. Started Oct 2014; status: completed.
02
Drugs
astodrimer
03
Conditions
bacterial vaginosis (BV)
Beyond the preview
Go deeper on NCT02237950.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02237950.